Pakistan vs Viet Nam: Average cost of multi drug-resistant tuberculosis treatment
Pakistan
460 constant 2022 US$
in 2024
Viet Nam
458 constant 2022 US$
in 2024
Pakistan rank
82nd
Viet Nam rank
83rd
Average cost of multi drug-resistant tuberculosis treatment over time
- Pakistan
- Viet Nam
How they compare
Pakistan currently reports 460 constant 2022 US$ against 458 constant 2022 US$ in Viet Nam, a difference of 2 constant 2022 US$.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Pakistan ahead.
Pakistan ranks 82nd and Viet Nam ranks 83rd of 92 countries.
Pakistan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Pakistan | Viet Nam | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,783 constant 2022 US$ | 713 constant 2022 US$ | 3,070 constant 2022 US$ | Pakistan |
| 2020s | 1,406 constant 2022 US$ | 570.2 constant 2022 US$ | 836.2 constant 2022 US$ | Pakistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Pakistan or Viet Nam?
- Pakistan, at 460 constant 2022 US$ against 458 constant 2022 US$ in Viet Nam as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Pakistan and Viet Nam?
- 2 constant 2022 US$, with Pakistan ahead.
- How many years of comparable data are there for Pakistan and Viet Nam?
- 8 years are reported by both, from 2017 to 2024.
- How do Pakistan and Viet Nam rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Pakistan ranks 82nd and Viet Nam ranks 83rd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.